acc0701 |
SIRT7 |
ubiquitination |
unclear |
human |
Hepatocellular Carcinoma |
Hep3B |
Sorafenib |
Enhancing |
5.0 |
37187452
|
acc0702 |
SIRT7 |
ubiquitination |
unclear |
human |
Hepatocellular Carcinoma |
SNU-449 |
Sorafenib |
Enhancing |
5.0 |
37187452
|
acc0703 |
AKT |
ubiquitination |
unclear |
human |
Gastric Cancer |
MGC803 |
Estradiol cypionate |
Associated |
4.0 |
37392652
|
acc0704 |
AKT |
ubiquitination |
unclear |
human |
Gastric Cancer |
SGC7901 |
Estradiol cypionate |
Associated |
4.0 |
37392652
|
acc0705 |
beta-catenin |
ubiquitination |
unclear |
human |
Pancreas Cancer |
MIA PaCa-2 |
Niclosamide + Gemcitabine |
Associated |
4.0 |
37917550
|
acc0706 |
4EBP1 |
phosphorylation |
Thr37 |
human |
Lung Cancer |
NCI-H196 |
Olaparib |
Impairing |
5.0 |
30201826
|
acc0707 |
4EBP1 |
phosphorylation |
Thr37 |
human |
Glioblastoma |
SNB-75 |
Olaparib |
Impairing |
5.0 |
30201826
|
acc0708 |
4EBP1 |
phosphorylation |
Thr37 |
human |
Glioblastoma |
SF-539 |
Olaparib |
Impairing |
5.0 |
30201826
|
acc0709 |
4EBP1 |
phosphorylation |
Thr37 |
human |
Glioblastoma |
U87-MG |
Olaparib |
Impairing |
5.0 |
30201826
|
acc0710 |
4EBP1 |
phosphorylation |
Thr46 |
human |
Lung Cancer |
NCI-H196 |
Olaparib |
Impairing |
5.0 |
30201826
|
acc0711 |
4EBP1 |
phosphorylation |
Thr46 |
human |
Glioblastoma |
SNB-75 |
Olaparib |
Impairing |
5.0 |
30201826
|
acc0712 |
4EBP1 |
phosphorylation |
Thr46 |
human |
Glioblastoma |
SF-539 |
Olaparib |
Impairing |
5.0 |
30201826
|
acc0713 |
4EBP1 |
phosphorylation |
Thr46 |
human |
Glioblastoma |
U87-MG |
Olaparib |
Impairing |
5.0 |
30201826
|
acc0714 |
4EBP1 |
phosphorylation |
Ser65 |
human |
Breast Cancer |
SK-BR-3 |
MLN0128 + TSA |
Associated |
4.0 |
24562770
|
acc0715 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
SK-BR-3 |
MLN0128 + TSA |
Associated |
4.0 |
24562770
|
acc0716 |
4EBP1 |
phosphorylation |
Ser65 |
human |
Breast Cancer |
MCF7 |
MLN0128 + TSA |
Associated |
4.0 |
24562770
|
acc0717 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
MCF7 |
MLN0128 + TSA |
Associated |
4.0 |
24562770
|
acc0718 |
4EBP1 |
phosphorylation |
Ser65 |
human |
Breast Cancer |
HER2-18 |
MLN0128 + TSA |
Associated |
4.0 |
24562770
|
acc0719 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
HER2-18 |
MLN0128 + TSA |
Associated |
4.0 |
24562770
|
acc0720 |
4EBP1 |
phosphorylation |
Ser65 |
human |
Breast Cancer |
BT474 |
MLN0128 + TSA |
Associated |
4.0 |
24562770
|
acc0721 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
BT474 |
MLN0128 + TSA |
Associated |
4.0 |
24562770
|
acc0722 |
4EBP1 |
phosphorylation |
Ser65 |
human |
Breast Cancer |
MDA-MB-231 |
MLN0128 + TSA |
Associated |
4.0 |
24562770
|
acc0723 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
MDA-MB-231 |
MLN0128 + TSA |
Associated |
4.0 |
24562770
|
acc0724 |
histone H3 |
acetylation |
Lys9 |
human |
Colorectal Cancer |
HCT116 |
5-FU |
Enhancing |
4.5 |
28139498
|
acc0725 |
AKT |
phosphorylation |
Ser473 |
human |
Colorectal Cancer |
HCT116 |
5-FU |
Enhancing |
5.0 |
28139498
|
acc0726 |
HSP90 |
acetylation |
lys |
human |
Breast Cancer |
SK-BR-3 |
Trastuzumab |
Enhancing |
5.0 |
21082217
|
acc0727 |
alpha-tubulin |
acetylation |
lys |
human |
Breast Cancer |
SK-BR-3 |
Geldanamycin |
Enhancing |
5.0 |
21082217
|
acc0728 |
CCAR2 |
acetylation |
Lys |
human |
Colorectal Cancer |
HCT116 |
Sulforaphane |
Associated |
4.0 |
30643017
|
acc0729 |
RelA |
acetylation |
Lys310 |
human |
Breast Cancer |
MDA-MB-231 |
BRD4 inhibitor 13a |
Associated |
4.0 |
34378541
|
acc0730 |
FOXO1 |
acetylation |
Lys |
human |
Lung Cancer |
PC9 |
Depsipeptide + Erlotinib |
Associated |
4.0 |
26036758
|
acc0731 |
FOXO1 |
acetylation |
Lys |
human |
Lung Cancer |
H1650 |
Depsipeptide + Erlotinib |
Associated |
4.0 |
26036758
|
acc0732 |
FOXO1 |
phosphorylation |
Thr24 |
human |
Lung Cancer |
PC9 |
Ku0063794 + Erlotinib |
Associated |
4.0 |
26036758
|
acc0733 |
FOXO1 |
phosphorylation |
Thr24 |
human |
Lung Cancer |
H1650 |
Ku0063794 + Erlotinib |
Associated |
4.0 |
26036758
|
acc0734 |
FOXO1 |
phosphorylation |
Thr24 |
human |
Lung Cancer |
PC9 |
LY294002 + Erlotinib |
Associated |
4.0 |
26036758
|
acc0735 |
FOXO1 |
phosphorylation |
Thr24 |
human |
Lung Cancer |
H1650 |
LY294002 + Erlotinib |
Associated |
4.0 |
26036758
|
acc0736 |
GD3 |
acetylation |
unclear |
human |
Medulloblastoma |
RES256 |
Etoposide |
Impairing |
5.0 |
31197190
|
acc0737 |
GLDC |
acetylation |
Lys514 |
human |
Glioblastoma |
U251 |
Rapamycin |
Associated |
4.0 |
34244482
|
acc0738 |
GLDC |
acetylation |
Lys514 |
human |
Glioblastoma |
U87 |
Rapamycin |
Associated |
4.0 |
34244482
|
acc0739 |
ERalpha |
methylation |
unclear |
human |
Breast Cancer |
MCF7 |
Tamoxifen |
Associated |
4.0 |
37458145
|
acc0740 |
6PGD |
methylation |
Arg324 |
human |
Lung Cancer |
|
Cisplatin |
Impairing |
5.0 |
36815049
|
acc0741 |
ENO1 |
methylation |
Arg9 |
human |
Lung Cancer |
|
Cisplatin |
Impairing |
5.0 |
36815049
|
acc0742 |
ENO1 |
methylation |
Arg372 |
human |
Lung Cancer |
|
Cisplatin |
Impairing |
5.0 |
36815049
|
acc0743 |
AR |
acetylation |
Lys609 |
human |
Prostate Cancer |
C4-2B |
(R)-9b |
Associated |
4.0 |
35704598
|
acc0744 |
AR |
phosphorylation |
Tyr267 |
human |
Prostate Cancer |
C4-2B |
(R)-9b |
Associated |
4.0 |
35704598
|
acc0745 |
AKT |
phosphorylation |
Ser473 |
human |
Cholangiocarcinoma |
QBC939 |
5-FU |
Enhancing |
5.0 |
25933112
|
acc0746 |
S6 |
phosphorylation |
Ser235 |
human |
Cholangiocarcinoma |
QBC939 |
5-FU |
Enhancing |
5.0 |
25933112
|
acc0747 |
S6 |
phosphorylation |
Ser236 |
human |
Cholangiocarcinoma |
QBC939 |
5-FU |
Enhancing |
5.0 |
25933112
|
acc0748 |
AKT |
phosphorylation |
Ser473 |
human |
Cholangiocarcinoma |
SK-ChA-1 |
5-FU |
Enhancing |
5.0 |
25933112
|
acc0749 |
S6 |
phosphorylation |
Ser235 |
human |
Cholangiocarcinoma |
SK-ChA-1 |
5-FU |
Enhancing |
5.0 |
25933112
|
acc0750 |
S6 |
phosphorylation |
Ser236 |
human |
Cholangiocarcinoma |
SK-ChA-1 |
5-FU |
Enhancing |
5.0 |
25933112
|